DK1599469T3 - Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed - Google Patents
Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermedInfo
- Publication number
- DK1599469T3 DK1599469T3 DK04818324T DK04818324T DK1599469T3 DK 1599469 T3 DK1599469 T3 DK 1599469T3 DK 04818324 T DK04818324 T DK 04818324T DK 04818324 T DK04818324 T DK 04818324T DK 1599469 T3 DK1599469 T3 DK 1599469T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- related disorders
- tetrazole derivatives
- treating metabolism
- metabolism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1599469T3 true DK1599469T3 (da) | 2006-10-09 |
Family
ID=34572875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04818324T DK1599469T3 (da) | 2003-10-31 | 2004-10-29 | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed |
Country Status (38)
Country | Link |
---|---|
US (2) | US8637555B2 (da) |
EP (2) | EP1599469B1 (da) |
JP (2) | JP4533898B2 (da) |
KR (1) | KR100850591B1 (da) |
CN (1) | CN1867562B (da) |
AR (1) | AR046611A1 (da) |
AT (1) | ATE328880T1 (da) |
AU (1) | AU2004287861B2 (da) |
BR (1) | BRPI0415631A (da) |
CA (1) | CA2539985C (da) |
CO (1) | CO5690551A2 (da) |
CR (1) | CR8270A (da) |
CY (1) | CY1105479T1 (da) |
DE (1) | DE602004001134T2 (da) |
DK (1) | DK1599469T3 (da) |
EA (1) | EA011484B1 (da) |
EC (1) | ECSP066529A (da) |
ES (1) | ES2267077T3 (da) |
GE (1) | GEP20094801B (da) |
HK (1) | HK1076468A1 (da) |
HR (1) | HRP20060286T3 (da) |
IL (1) | IL174042A0 (da) |
IS (1) | IS2372B (da) |
MA (1) | MA28171A1 (da) |
MX (1) | MXPA06004556A (da) |
MY (1) | MY140410A (da) |
NO (1) | NO20062509L (da) |
NZ (1) | NZ546285A (da) |
PE (1) | PE20050483A1 (da) |
PL (1) | PL1599469T3 (da) |
PT (1) | PT1599469E (da) |
RS (1) | RS20060290A (da) |
SI (1) | SI1599469T1 (da) |
TN (1) | TNSN06150A1 (da) |
TW (1) | TWI258478B (da) |
UA (1) | UA86783C2 (da) |
WO (1) | WO2005044816A1 (da) |
ZA (2) | ZA200603419B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
CA2545823A1 (en) | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
AU2005305086A1 (en) * | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) * | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
EP1901731B1 (en) | 2005-06-28 | 2011-03-02 | Merck Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
AP2015008670A0 (en) | 2013-02-21 | 2015-08-31 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
JP6453216B2 (ja) * | 2013-07-23 | 2019-01-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ縮合環化合物 |
CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
CA3096145A1 (en) * | 2019-10-11 | 2021-04-11 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
ATE443698T1 (de) | 1996-12-23 | 2009-10-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterocyclen als faktor xa- hemmer |
EP1067109B1 (en) | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
NZ521192A (en) | 2000-03-09 | 2005-01-28 | Ono Pharmaceutical Co | Indole derivatives, process for preparation of the same and use thereof |
US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
CN1245974C (zh) | 2000-06-28 | 2006-03-22 | 特瓦制药工业有限公司 | 卡维地洛 |
TW200914443A (en) | 2000-06-30 | 2009-04-01 | Glaxo Group Ltd | Process for preparing substituted quinazolinyl furanaldehyde |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
AU2002302248B2 (en) | 2001-05-23 | 2008-03-06 | Merck Frosst Canada Ltd. | Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists |
ES2332505T3 (es) | 2001-06-01 | 2010-02-08 | F. Hoffmann-La Roche Ag | Derivados de pirimidina, triazina y pirazina como receptores de glutamato. |
AU2002316421B2 (en) | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
EP1292602B1 (en) | 2001-06-27 | 2004-04-07 | RS Tech Corp. | New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst |
JPWO2003022814A1 (ja) | 2001-09-07 | 2004-12-24 | 小野薬品工業株式会社 | インドール誘導体化合物 |
DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
NZ535309A (en) | 2002-03-19 | 2006-05-26 | Ono Pharmaceutical Co | Carboxylic acid compounds and drugs containing the compounds as the active ingredient |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
US20060167270A1 (en) * | 2002-10-10 | 2006-07-27 | Arena Pharmaceuticals Inc. | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2005011677A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
PE20050483A1 (es) * | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
PL1781657T3 (pl) | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
US20070244107A1 (en) | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
AU2005305086A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en active IP Right Grant
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de active Active
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 EP EP04818324A patent/EP1599469B1/en not_active Not-in-force
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active IP Right Cessation
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 EP EP06005248A patent/EP1683794A1/en not_active Withdrawn
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es active Active
-
2005
- 2005-12-06 HK HK05111162A patent/HK1076468A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-08-24 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
IS7977A (is) | Samsetningar og aðferð til samsettra meðferðar | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
IS8037A (is) | P38-hindrar og aðferðir til notkunar þeirra | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
DK1628530T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis | |
DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
DK1673104T4 (da) | Fremføring af terapeutiske forbindelser til hjernen og andre væv | |
DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
DK1891571T3 (da) | Hæmning af spredning af uønskede koder og data | |
DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
DK1701944T3 (da) | 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme | |
DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
DK1599469T3 (da) | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed | |
NO20053874D0 (no) | Formulering og metoder for behandling av thrombocytemi | |
DK1750713T3 (da) | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner | |
DK1611890T3 (da) | Fremgangsmåde til evaluering og behandling af cancer | |
IS8497A (is) | Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma | |
DK1667730T3 (da) | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom | |
DK1596868T3 (da) | Fremgangsmåde til behandling af hjertesvigt og medikament dertil |